The NCI Laboratory of Cellular and Molecular Biology seeks statements of capability or interest from parties interested in licensing this novel inhibitor of the Hippo signaling pathway.
The National Eye Institute (NEI) seeks research collaborations and/or licensees for the use of iPS cells.
Gammaretroviral vectors were the first viral gene-therapy vectors to enter clinical trials and remain in use. One potential hazard associated with the use of such vectors is the presence of replication-competent retroviruses (RCR) in the vector preparations – either as a result of: 1) recombination events between the plasmids used for vector production, 2) interactions between the plasmids and endogenous retroviral sequences in the packaging cell lines, or 3) as a result of contamination in the laboratory.
The NCI Laboratory of Molecular Biology is seeking parties interested in licensing a genetically engineered mouse model expressing hMSLN in the thyroid gland for commercialization in the field of cancer therapeutics and research targeting mesothelin-expressing tumors.
The National Cancer Institute (NCI) seeks co-development partners and/or licensees for polymer-cast inserts for cell histology and microscopy; a system for high throughput three-dimensional (3D) cell culture and screening microscopy.
The NCI is seeking licensees for the SLC46A3 knockout mouse line.
Nonalcoholic fatty liver disease is caused by several factors including 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), an environmental contaminant. TCDD causes lipid accumulation in humans by inducing the Solute Carrier Family 46 Member 3 (SLC46A3) gene expression. To effectively study TCDD-mediated lipid accumulation, research tools such as SLC46A3 knockout cells and animal models are required.
The Centers for Disease Control and Prevention (CDC) and the National Institute for Allergy and Infectious Diseases (NIAID) have been rewarded for their partnership from the 2021 Federal Laboratory Consortium (FLC) awards. The CDC and NIAID had already developed a new approach to sharing samples during a Public Health Emergency of International Concern (PHEIC) during the Zika pandemic, which enabled them to respond quickly and efficiently to access and share samples of SARS-CoV-2 early in the outbreak.
Within hours of the public release of the viral genome sequence, scientists at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) and their collaborators engineered a key protein from SARS-CoV-2, the virus that causes COVID-19, to enable its study as a vaccine candidate and for research applications.
In recognition of pioneering research and development that has brought NIH technology from the theoretical realms of the laboratory to clinical applications.
Awardee
National Heart Lung and Blood Institute